Author： Sermet-Gaudelus I. Stoven V. Annereau J.P . Witko-Sarsat V. Reinert P . Guyot M. Descamps-Latscha B. Lallemand J.Y. Lenoir G.
Publisher： Informa Healthcare
ISSN： 1466-1861
Source： Mediators of Inflammation, Vol.8, Iss.1, 1999-02, pp. : 13-15
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
CYSTIC fibrosis (CF) lung disease is characterized by persistent inflammation. Antiinflammatory drugs, such as corticosteroids and ibuprofene, have proved to slow the decline of pulmonary function although their use is limited because of frequent adverse events. We hypothesized that colchicine could be an alternative treatment because of its antiinflammatory properties and upregulatory effect on cystic fibrosis transmembrane regulator (CFTR) closely related proteins. We herein present results obtained in an open study of eight CF children treated with colchicine for at least 6 months. Clinical status was better in all patients and respiratory function tests significantly improved in five. Median duration of antibiotherapy decreased significantly. These preliminary results support our hypothesis of a beneficial effect of colchicine in CF patients and stress the need for a controlled therapeutic trial.
Related content
Diagnosis and Treatment of Cystic Fibrosis
Respiration, Vol. 67, Iss. 3, 2009-01 ,pp. :
Access to resources
Recommend
Treatment of Cystic Fibrosis in the Adult
Respiration, Vol. 67, Iss. 6, 2000-12 ,pp. :
Respiration, Vol. 87, Iss. 6, 2014-05 ,pp. :
Treatment of pulmonary exacerbations in cystic fibrosis
By Smith Daniel J Reid David W Bell Scott C
Therapy, Vol. 8, Iss. 6, 2011-11 ,pp. :